Pralsetinib Production Cost Reports

The report provides a detailed analysis essential for establishing a pralsetinib production plant. It encompasses all critical aspects necessary for pralsetinib production, including the cost of pralsetinib production, pralsetinib plant cost, pralsetinib production costs, and the overall pralsetinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a pralsetinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Pralsetinib is a medication that is designed to target specific genetic alterations in the RET gene that drive certain advanced cancers. It is approved for treating adults with metastatic non-small cell lung cancer (NSCLC) that has RET fusion-positive mutations. It is utilised in advanced or metastatic RET-mutant medullary thyroid cancer (MTC) in adults and pediatric patients aged 12 years and older.

It is also used in RET fusion-positive thyroid cancer that has become unresponsive to radioactive iodine treatment. It binds with the ATP-binding site of the RET kinase and effectively blocks downstream oncogenic signalling pathways responsible for tumour cell proliferation, survival, and metastasis. It provides a precision medicine approach that saves healthy cells and reduces off-target toxicities compared to less selective therapies.

The market for pralsetinib is driven by increasing cases of RET-altered cancers like non-small cell lung cancer and thyroid cancers. This is fuelled by higher biomarker testing adoption rates, FDA approvals that broaden patient access, and durable efficiency in progression-free survival and duration of response. The competition with alternatives like selpercatinib divides the RET inhibitor market, which affects its demand.

Its usage among adults and pediatric patients aged 12 years and older. The industrial pralsetinib procurement is influenced by high per-patient acquisition expenses, reliable supply chains, and patient access programs that offer discounts to ease costs. Overall, regulatory expansions, orphan drug status, and sustained sales affect its sourcing and pricing among healthcare systems and distributors.

Raw Material for Pralsetinib Production

According to the pralsetinib production plant project report, the key raw materials used in the production of pralsetinib include bromopyridine, boronate, and amine.

Production Process of Pralsetinib

The extensive pralsetinib production cost report consists of the following major industrial production process:

1. By Suzuki coupling: The production process of pralsetinib starts with the bromopyridine. It goes through Suzuki coupling with boronate. The reaction takes place under standard conditions using a Pd catalyst, base, toluene and ethanol at an elevated temperature that forms acetonide. This converts to a ketone by acidification with HCl in acetone. After that, Takenori homologation connects the quaternary carbon in the intermediate, followed by amide coupling with amine that forms high-purity pralsetinib.

Pralsetinib has the molecular formula of C27H32FN9O2 with a molecular weight of 533.6 g/mol. It appears as a white to off-white solid and exists in multiple crystalline polymorphs, Forms II, III, IV, V, VI, and VII. It has a logP value of 3.1 that makes it moderately lipophilic. It has three hydrogen bond donors, nine acceptors, eight rotatable bonds, and a topological polar surface area of 136 square angstroms. It has a predicted pKa value of 14.33 and structural motifs like aminopyrimidinyl and methylaminopyrazolyl groups that enable precise binding to the RET kinase hinge region. All these physical and chemical properties contribute to its favourable oral bioavailability.